Methods for treating breast cancer and for identifying breast cancer antigens
AssigneeUniversity of Connecticut
InventorsDavid Han, Veneta Qendro
Life of this patent
Estimating the term…
Abstract
Disclosed herein are isolated compositions including at least 2 of mutant peptides selected from the group consisting of SEQ ID NOS: 1-149, or polypeptides comprising the mutant peptides; wherein the composition comprises mutant peptides encoded by 2 or more genes. Also disclosed are methods for personalized treatment of breast cancer involving creating a peptide array of mutant peptides comprising the mutations in protein-encoding regions of the high-frequency cancer genes or the exome in a subject and screening the peptide array with a biological sample from the subject to detect antibodies in the biological sample that bind to the array, to detect antigenic targets for therapy in treating the subject.
Claims11
A method for identifying antigenic targets for breast cancer treatment, comprising:
- (a) contacting a peptide array with a biological sample from a subject having breast cancer, wherein the peptide array comprises at least 25 mutant peptides selected from the group consisting of SEQ ID NOS:
- 1-82, 84-91, and 93-149, or polypeptides comprising the mutant peptides;
- wherein the array comprises mutant peptides encoded by 10 or more genes, and wherein the mutant peptides are fluorescently labeled;
- (b) detecting binding of antibodies in the serum to the mutant peptides and the wild-type counterparts thereof, thus identifying antigenic targets for therapy in treating the subject.
A method for monitoring breast cancer immunotherapy, comprising
- (a) contacting a biological sample from a subject who is undergoing or has undergone breast cancer immunotherapy with an isolated composition, comprising at least 25 mutant peptides selected from the group consisting of SEQ ID NOS:
- 1-82, 84-91, and 93-149, or polypeptides comprising the mutant peptides;
- wherein the composition comprises mutant peptides encoded by 10 or more genes;
- and
- (b) determining an amount of antibodies against the mutant peptides in the bodily fluid sample;
- wherein an increase in the amount of antibodies relative to a control, such as a baseline level of antibodies in a similar bodily fluid sample from the subject indicates efficacy of the breast cancer immunotherapy in the subject;
- and
- wherein a decrease or no increase in the amount of antibodies relative to a control, such as a baseline level of antibodies in a similar bodily fluid sample from the subject indicates that the immunotherapy is ineffective in the subject.
Dependencies are inferred from the claim text.